{"url_path":"/sec/autl/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000065-index.html","accession_number":"0001730463-26-000065","cik":"0001730463","ticker":"AUTL","issuer_name":"Autolus Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000065-index.html","primary_entity_key":"0001730463","primary_entity_name":"Autolus Therapeutics plc"},"word_count":139,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nInsider Trading Arrangements\n\nDuring the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K.\n\nResignation of John Berriman as Director\n\nOn May 13, 2026, Mr. John Berriman, a member of the board of directors of the Company since 2014, notified the Company of his intention not to stand for re-election at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Berriman has indicated that this decision was not the result of any disagreement with the Company’s management or Board. The Company thanks Mr. Berriman for his dedicated service to the Company and wishes him well in his future endeavors."}